New Cholesterol Drug Could be Statin Alternative
11.03.10
Statins are the drugs most often prescribed to treat high cholesterol, but they often cause troubling side effects or are not effective. A new cholesterol lowering drug substance called eprotirome that showed no serious side effects could eventually be a statin alternative.
The American Heart Association notes that a staggering 102.2 million adults in the United States have blood cholesterol levels of 200 mg/dL or greater. This value is recognized as the dividing line between “normal” and “borderline-high risk” (200 to 239 mg/dL). Of the 102.2, about 35.7 million American adults have levels of 240 mg/dL or higher, which is considered high risk.
People with high cholesterol have about twice the risk of the number one killer in America-- heart disease --as people who have optimal levels, according to the Centers for Disease Control and Prevention (CDC). High cholesterol is also a risk factor for stroke.
A team of researchers from Karolinska Institutet and several other centers have found that a substance called eprotirome can reduce blood cholesterol levels by acting specifically on the liver, which is the main cholesterol-producing site in the body. They made this discovery during a three-month trial that included 189 patients who had already been treated with statins.
Source: eMaxHealth
Obama's physical: Who decided an LDL of 138 is bad – or that an annual checkup ...
01.03.10
It can't be easy to be president. Your zone of privacy is so very small — and we want to know everything. Given that context, it seems obnoxious to stand in judgment of the president's having recently undergone a physical exam [PDF]. Or the nature in which the leader of the free world had his colon scanned for tumors. Or to chew over his blood lipid profile the way one would the latest Zogby polling data.
But the president has embraced best practices as one of his goals for the reform of health care — frequently referencing Mayo Clinic as a shining example, in fact. That is nothing if not worthy, given the enormous waste generated within American health care because of screenings and treatments that hold cultural favor and are masterfully marketed and that must surely hold totemic status within related medical specialties, but which, alas, are not supported by evidence. Too bad his personal physicians appear to have missed the troubling disconnect between their practices over the weekend and the president's policy proposals.
Source: MinnPost.com (blog)
Diabetes Risk of Statins Outweighed by Heart Benefit
17.02.10
Family Physicians: 0.25 Elective credits
Release Date:
Feb. 17, 2010
Expiration Date:
Feb. 17, 2011
Estimated time for completion: 15 minutes
There is no fee for this activity.
To Receive Credit In order to receive your certificate of participation, you should read the information about this activity, including the disclosure statements, review the entire activity, take the post-test, and complete the evaluation form. You may then follow the directions to print your certificate of participation.
Program Overview
Among the many issues clinicians face today, staying current with advances in medicine is becoming a major challenge. Teaching Brief® articles will allow clinicians to stay up-to-date and assimilate new information into their daily practice. The content of these Teaching Brief articles has been validated
Source: MedPage Today
Gli introiti di Bristol Myers arrivano principalmente dalla vendita di medicine come il Plavix, contro le malattie cardiache, il Pravachol, per ridurre il